A new trading day began on Tuesday, with Spyre Therapeutics Inc (NASDAQ: SYRE) stock price down -11.64% from the previous day of trading, before settling in for the closing price of $17.18. SYRE’s price has ranged from $10.91 to $40.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 4.31%. With a float of $51.32 million, this company’s outstanding shares have now reached $60.28 million.
The extent of productivity of a business whose workforce counts for 65 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Spyre Therapeutics Inc (SYRE) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Spyre Therapeutics Inc is 14.97%, while institutional ownership is 99.38%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 4.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.68% during the next five years compared to 44.65% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Here are Spyre Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -3.30 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
The latest stats from [Spyre Therapeutics Inc, SYRE] show that its last 5-days average volume of 0.7 million was superior to 0.63 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 37.64%. Additionally, its Average True Range was 1.15.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 30.68%, which indicates a significant increase from 23.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.17% in the past 14 days, which was lower than the 74.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.75, while its 200-day Moving Average is $22.76. Now, the first resistance to watch is $17.03. This is followed by the second major resistance level at $18.88. The third major resistance level sits at $20.43. If the price goes on to break the first support level at $13.63, it is likely to go to the next support level at $12.08. Assuming the price breaks the second support level, the third support level stands at $10.23.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
With a market capitalization of 916.16 million, the company has a total of 60,276K Shares Outstanding. Currently, annual sales are 0 K while annual income is -208,020 K. The company’s previous quarter sales were 0 K while its latest quarter income was -44,770 K.
